CClinicalTrials.gg
CompletedNCT03294473Updated Jun 5, 2019

Centralized Reminder Recall - Flu RCT2

An interventional study of R/R - Autodialers and R/R - Texting in Influenza, Human, Orthomyxoviridae Infections and RNA Virus Infections, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
70,190
Allocation
Randomized
Ages
6 Months to 17 Years
Sex
All
01

Study summary

This study is related to a previous study, Clinicaltrials.gov ID: NCT02924467. There are some modifications in relation to the intervention arms as well as the use of a different cohort, thereby justifying the second submission to Clinicaltrials.gov. This trial is taking place in New York State, through partnership with the New York State Health Department (excluding New York City), and Colorado. Each state will have it's own Clinicaltrial.gov submission -- this was decided as some of the intervention components are different enough that separate registrations were warranted.

Despite U.S. guidelines for influenza vaccination of all children starting at 6 months, only about half of children are vaccinated annually leading to substantial influenza disease in children and spread of disease to adults. A major barrier is that families are not reminded about the need for their children to receive influenza vaccination. The investigators will evaluate the impact of patient reminder/recall (R/R) performed by state immunization information systems to improve influenza vaccination rates by using 4 clinical trials (2 per state) in two different states. The investigators will assess effectiveness and cost-effectiveness of 1) autodialer R/R 2) text messages R/R 3) mailed postcard R/R as compared to 4) standard of care control (no R/R).

Read the detailed description

Annual epidemics of influenza A and B cause substantial morbidity and mortality in the US with high rates of hospitalizations, emergency department visits, outpatient visits, and medical costs. Epidemics cause up to 40,000 deaths/year (mostly elderly) and extensive morbidity among children who play a key role in instigating and expanding epidemics. In addition, concerns about pandemic influenza heighten the importance of new mechanisms to rapidly inform the population about influenza and direct efforts for rapid vaccine delivery.

Since 2010, the Advisory Committee on Immunization Practices (ACIP) has recommended influenza vaccination for all children >6 months of age. However, vaccination rates remain very low. For the 2012-2013 season, only 56% of children 2-17years were vaccinated. Modeling studies suggest that as many as 19 million cases of influenza could be prevented if child vaccination rates were raised to 70% nationally.

The most effective strategy recommended by CDC and the Task Force on Community Preventive Services for improving childhood influenza vaccination rates is reminder/recall (R/R), sent by phone or mail, notifying parents of the need to vaccinate their child. We and others have shown that R/R can improve influenza vaccination rates by up to 20%. However, \<16% of practices use R/R; barriers are practice costs, insufficient staff time and expertise, and lack of predictability regarding receipt of vaccine supplies.

Statewide immunization information systems (IISs) now exist in all states to track childhood vaccinations, but they have not been used for influenza vaccine R/R because of lack of evidence for their effectiveness and a lack of a template for IIS-based R/R. The investigators have united two leading immunization research groups (Denver, CO and Rochester (lead by personnel at UCLA), NY) to assess the impact of centralized IIS-based influenza vaccine R/R and to evaluate the effect of three types of R/R (autodialer, text message and mail R/R) over usual care. The investigators will also develop tools to aid other states in creating efficient IIS R/R systems for seasonal and possible pandemic influenza outbreaks.

For this second R/R trial in New York State, the intent is to evaluate the impact of reminder recalls, in the form of 1) autodialers 2) text messages and 3) postcards versus the standard of care control group, specifically in relation to raising influenza vaccination rates among children 6m-17 years of age.

The proposed design of this 4-arm RCT:

  1. standard of care control
  2. autodialer R/R -- with brief educational messages, practice name and practice phone number
  3. text message R/R-- with brief educational messages, practice name and practice phone number
  4. mailed (postcards) R/R-- with brief educational messages, practice name and practice phone number

Hypothesis 1: All IIS-C R/R modalities will be more effective than usual care

Hypothesis 2: Text messaging will be more cost-effective than other modalities

02

Conditions studied

  • Influenza, Human
  • Orthomyxoviridae Infections
  • RNA Virus Infections
  • Virus Disease
  • Respiratory Tract Infections
  • Respiratory Tract Disease
  • Vaccines
  • Physiological Effects of Drugs

Keywords

  • reminder recall (R/R), influenza vaccines
03

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • a record in the New York State Immunization Information System
  • in need of at least one influenza vaccination at the time of the beginning of the study
  • affiliated with a participating practice (145 randomly selected)

Exclusion criteria

Exclusion Criteria:

  • no record within the New York State Immunization Information System
  • up to date on their influenza vaccination
  • not affiliated with an eligible practice
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70,190 participants (actual)

Study arms

  • Experimental
    Autodial R/R

    R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number

    Behavioral: R/R - Autodialers

  • Experimental
    Text Message R/R

    R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number

    Behavioral: R/R - Texting

  • Experimental
    Postcard R/R

    R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number

    Behavioral: R/R - mailed postcard

  • No intervention
    Standard of Care Control

    Participants in this group will not receive any influenza vaccination reminders

Interventions

  • BehavioralR/R - Autodialers

    Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).

  • BehavioralR/R - Texting

    Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).

  • BehavioralR/R - mailed postcard

    Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).

05

What researchers measure

Primary outcomes

  1. The primary outcome is receipt of influenza vaccine comparing effectiveness of standard of care control to autodialer, text message and postcard R/R

    Based on our prior studies, we plan to send up to 3 autodialer, text messages or postcards (based on randomization) reminders, roughly every 5-6 weeks. This will begin in October 2017 and end in December 2017. Outcomes are assessed at 6 months using IIS data.

    Time frame: 6 months

Secondary outcomes

  1. Cost of the R/R intervention

    A cost-effectiveness analysis will be conducted to determine which modality of R/R (autodialer, text message or mailed postcard) is the most cost-effective in relation to improving influenza vaccination rates. The cost analysis will also compare autodialer to text, autodialer to postcard, and texting to postcards.

    Time frame: 6 months

06

Study locations

1 site
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
07

References and documents

Publications

  • Szilagyi PG, Albertin CS, Saville AW, Valderrama R, Breck A, Helmkamp L, Zhou X, Vangala S, Dickinson LM, Tseng CH, Campbell JD, Whittington MD, Roth H, Rand CM, Humiston SG, Hoefer D, Kempe A. Effect of State Immunization Information System Based Reminder/Recall for Influenza Vaccinations: A Randomized Trial of Autodialer, Text, and Mailed Messages. J Pediatr. 2020 Jun;221:123-131.e4. doi: 10.1016/j.jpeds.2020.02.020. PubMed 32446470 ↗

Individual participant data

Plan to share: No — Aggregate results will be prepared for publication at the end of the trial.

08

Registry details

Key details

Study ID
NCT03294473
Lead sponsor
University of California, Los Angeles
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), New York State Department of Health, University of Colorado, Denver
Responsible party
Peter G Szilagyi, MD MPH (Executive Vice Chair, Clinical Research, UCLA David Geffen School of Medicine, Dept of Pediatrics, University of California, Los Angeles) — Principal investigator
First posted
Sep 27, 2017
Start date
Oct 18, 2017
Primary completion
Apr 19, 2018
Completion
May 4, 2018
Last update
Jun 5, 2019

Study contacts

Peter Szilagyi, MD, MPH
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion